Original reporting and analysis on the stories shaping biotech.
GSK's Jemperli just hit its primary endpoint in a rectal cancer trial, building on a streak where every single patient's tumor vanished without surgery. The implications for how we treat cancer are bigger than one drug.
Roche's divarasib just beat both Amgen's sotorasib and BMS's adagrasib head-to-head in a Phase 3 lung cancer trial, hitting survival endpoints that could reshape KRAS G12C treatment. Wall Street is cautiously optimistic, but the real prize is still up for grabs.
Congo's Ebola outbreak just spread to two new provinces, and here's the problem: the approved vaccines don't work against this strain. Oxford is racing to change that with the first-ever human trial of a Bundibugyo-specific vaccine, built on the same platform as the AstraZeneca COVID shot.
Chinese biotech companies inked $110 billion in out-licensing deals in just six months, a record that puts 2026 on pace to demolish last year's total. Every major Western pharma company is now shopping in China, and the carts keep getting bigger.
The FDA just approved an at-home starting dose for Leqembi, letting Alzheimer's patients skip the infusion center entirely. It's not just a convenience upgrade; it could unclog the biggest bottleneck holding back the first drug to actually slow the disease.
J&J's blockbuster immunology drug Stelara saw its Q2 revenue plunge 43% as biosimilar copycats flooded the market. But somehow the company posted record pharma sales and sent the stock soaring. Here's how they pulled it off.
AstraZeneca and Tempus AI built an AI framework that retroactively improved survival in cancer trials by 15%, not by changing the drug, but by picking better patients. The real test: can it work prospectively?
Casgevy, one of the first CRISPR therapies ever approved, can essentially cure sickle cell disease. But a bizarre bottleneck at the very first step of treatment is preventing most patients from ever getting it. Only about 60 people have been treated in over two years.
The FDA just approved a CRISPR gene therapy for sickle cell patients as young as two years old, potentially offering a cure before the disease can cause lasting damage. But the $2.2 million price tag and chemo conditioning raise questions about who actually gets access.
The FDA's vaccine advisory panel voted 9-0 that Moderna's mRNA flu shot was safe and effective. Then the agency rejected it anyway, on trial design grounds that blindsided the industry. The fallout could reshape how vaccine makers think about U.S. development for years.
The FDA just unveiled a new framework that lets gene therapies win approval based on biological plausibility rather than massive clinical trials, and ARPA-H is backing it with $160 million. For the 95% of rare diseases with zero approved treatments, this could change everything.
A tiny trial at Dana-Farber gave CAR-T therapy to patients who didn't have cancer yet, just a high-risk precursor condition. Every single patient responded, and the results could rewrite the rules of when we fight cancer.
The FDA just cleared Keytruda plus Padcev for muscle-invasive bladder cancer with no cisplatin requirement, filling a gap that left nearly half of patients without effective perioperative therapy. The clinical data is striking: 57% of patients had zero detectable cancer at surgery.
AstraZeneca is paying up to $1.77 billion to access a Chinese pharma company's technology for delivering RNA drugs beyond the liver. Every approved siRNA drug today only works in one organ, and cracking the code for kidneys could reshape the entire field.
An American doctor in Congo just tested positive for a strain of Ebola that has no approved vaccine and no proven treatment. Now the U.S. government and a handful of biotechs are in a dead sprint to build the countermeasures that should have existed years ago.
ARPA-H just handed $160 million to seven teams tasked with turning custom gene editing from a $4 million luxury into a scalable platform. The targets: rare childhood diseases. The timeline: patients dosed within three years.
A nominee for the office that coordinates America's pandemic response has called mRNA vaccines "reckless" and promoted the debunked vaccines-autism link. Public health experts are sounding alarms, and vaccine makers are quietly rethinking their U.S. strategies.
The FDA is shutting down the booming market for cheap, compounded versions of Ozempic and Mounjaro. Billions in revenue are headed back to Novo Nordisk and Eli Lilly, but millions of patients could lose their most affordable option.
Eli Lilly is selling Zepbound in cheaper single-dose vials through its direct platform, dropping monthly costs to as low as $299. It's a direct counterpunch to Novo Nordisk's aggressive Wegovy discounting, and the GLP-1 price war is only getting started.
Novo Nordisk is offering Wegovy at nearly 30% off through Netflix-style subscription plans for cash-pay patients. It's a bold pricing play, but with Eli Lilly's Zepbound already dominating U.S. prescriptions, is it enough to turn the tide?
Ipsen just dropped up to €700 million on a Swiss biotech's antibody that targets a virus most people have never heard of. The catch: it's the only thing in development for a condition that wrecks transplanted kidneys, and the Phase II results are messy enough to make things interesting.
AstraZeneca and Ionis' gene-silencing drug eplontersen did everything right biologically in a massive ATTR cardiomyopathy trial, yet still failed to keep patients alive or out of the hospital. The reason why could reshape how the entire industry thinks about combination therapy.
Join thousands of biotech professionals who start their day with our free, daily briefing.